Anticancer drugs: How to select small molecule combinations?

Area of Science:

• Oncology
• Pharmacology
• Genomics

Background:

• Single-agent anticancer therapies often lead to acquired drug resistance.
• Understanding cancer's disruption of cellular processes is key to effective treatment.
• Combination therapies offer a promising strategy to overcome resistance and target multiple pathways.

Purpose of the Study:

• To provide a comprehensive guide for oncologists on selecting combinatorial anticancer therapy.
• To address the complexities of choosing drug combinations based on molecular targets and patient-specific factors.
• To elucidate the mechanistic basis of combination therapy selection.

Main Methods:

• Review of current anticancer small molecule drugs and their targets.
• Analysis of cancer-related pathways and gene expression profiles.
• Exploration of challenges in combination therapy, including pathway crosstalk.

Main Results:

• Identification of key factors influencing combinatorial therapy selection (target proteins, pathways, gene expression).
• Discussion of the advantages and challenges of targeting multiple pathways simultaneously.
• Presentation of examples and mechanistic insights for various combination strategies.

Conclusions:

• Comprehensive combinatorial therapy selection requires a multi-faceted approach.
• Understanding molecular mechanisms is crucial for optimizing treatment outcomes.
• This guide serves as a foundational resource for navigating complex anticancer drug combinations.